Walgreens has been sued by Arkansas Attorney General Leslie Rutledge, and the case was filed earlier this week. In her filing, she claimed that the pharmacy chain company played a big part in making the opioid crisis situation in the state worse.
Rutledge accused Walgreens of rendering a large number of orders for painkillers, and most of them are suspicious. The lawyer said that this is a violation of Arkansas’ Deceptive Trade Practices Act.
The lawsuit against Walgreens
The lawsuit was filed in Pulaski County Court, and it was stated that the pharmacy did not do enough to make sure that the prescriptions are legitimate and not questionable. It was said that because of Walgreens' failure to monitor the orders, large amounts of the regulated drug were distributed in Arkansas, as per Arkansas Democrat Gazelle.
"Walgreens has a legal responsibility to report suspicious orders and suspicious prescriptions," the attorney general said. "By failing to do so they enabled the black market of prescription drugs to increase dramatically, thus leading to more, greater addiction and more lives lost in the state of Arkansas."
As stated in the lawsuit, from 2006 to 2014, Walgreens fulfilled orders of over 142 million dosages of oxycodone and hydrocodone in the state. Rutledge said that this big amount should have alerted the company to the fact that suspicious orders were being placed.
It was added that such quantities that were distributed in Arkansas far exceeded the normal amount that could be consumed for medical legit purposes. “Walgreens failed to report and halt those orders and instead increased the number of pills distributed,” the statement from the suit reads.
With the filing, the state is seeking a directive that will force Walgreens to act responsibly and comply with federal and state laws. It is also seeking appropriate civil penalties for every violation that the company may have committed against the state’s consumer protection laws.
Walgreens denies the allegations
Walgreens refuted the accusations and stated that it never produced or marketed opioids. The company’s spokesperson further told FOX Business that they never sold the said drug to pain clinics, online pharmacies, and 'pill mills' that worsened the opioid crisis.
"Prior to 2014, we delivered opioids only to our own pharmacies, and the only place we ever sold FDA-approved opioid medications was at the pharmacy counter when presented with valid prescriptions written by DEA-licensed physicians for legitimate medical needs," the firm’s spokesperson said.
Finally, he added that the company’s pharmacists always evaluate and take the law into consideration before deciding whether to fill a prescription for controlled substances.


Boeing Secures $166.8 Million U.S. Navy Contract for P-8A Engineering and Software Support
APEX Tech Acquisition Inc. Raises $111.97 Million in NYSE IPO Under Ticker TRADU
Trump Orders Federal Agencies to Halt Use of Anthropic AI Technology
Hyundai Motor Group to Invest $6.26 Billion in AI Data Center, Robotics and Renewable Energy Projects in South Korea
Meta Signs Multi-Billion Dollar AI Chip Deal With Google to Power Next-Gen AI Models
Panama Investigates CK Hutchison’s Port Unit After Court Voids Canal Contracts
Amazon’s $50B OpenAI Investment Tied to AGI Milestone and IPO Plans
Lynas Rare Earths Shares Surge on Strong Half-Year Earnings and Rising Global Demand
Netflix Declines to Raise Bid for Warner Bros. Discovery Amid Competing Paramount Skydance Offer
OpenAI Hires Former Meta and Apple AI Leader Ruomin Pang Amid Intensifying AI Talent War
Samsung and SK Hynix Shares Hit Record Highs as Nvidia Earnings Boost AI Chip Demand
FAA Plans Flight Reductions at Chicago O’Hare as Airlines Ramp Up Summer Schedules
Greg Abel’s First Berkshire Hathaway Shareholder Letter Signals Continuity, Caution, and Capital Discipline
Middle East Airspace Shutdown Disrupts Global Flights After U.S.-Israel Strikes on Iran
OpenAI Pentagon AI Contract Adds Safeguards Amid Anthropic Dispute
Snowflake Forecasts Strong Fiscal 2027 Revenue Growth as Enterprise AI Demand Surges 



